Tuberculosis drugs’ distribution and emergence of resistance in patient’s lung lesions: A mechanistic model and tool for regimen and dose optimization.

PLoS medicine, Volume: 16, Issue: 4
April 2, 2019
Natasha Strydom N, Sneha V Gupta SV, William S Fox WS, Laura E Via LE, Hyeeun Bang H, Myungsun Lee M, Seokyong Eum S, TaeSun Shim T, Clifton E Barry CE, Matthew Zimmerman M, VĂ©ronique Dartois V, Radojka M Savic RM

The sites of mycobacterial infection in the lungs of tuberculosis (TB) patients have complex structures and poor vascularization, which obstructs drug distribution to these hard-to-reach and hard-to-treat disease sites, further leading to suboptimal drug concentrations, resulting in compromised TB treatment response and resistance development. Quantifying lesion-specific drug uptake and pharmacokinetics (PKs) in TB patients is necessary to optimize treatment regimens at all infection sites, to identify patients at risk, to improve existing regimens, and to advance development of novel regimens. Using drug-level data in plasma and from 9 distinct pulmonary lesion types (vascular, avascular, and mixed) obtained from 15 hard-to-treat TB patients who failed TB treatments and therefore underwent lung resection surgery, we quantified the distribution and the penetration of 7 major TB drugs at these sites, and we provide novel tools for treatment optimization.

Courtesy of the U.S. National Library of Medicine